CCCC
C4 Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
C4 Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
C4 Therapeutics has 1 disclosed supplier and 5 disclosed customers in SEC filings.
C4 Therapeutics, Inc.
3.36
Sentence• a $2.0 million increase in revenue recognized under our former exclusive license and collaboration agreement with Merck upon receipt of notice of termination in September 2025.
Sentence• a $2.9 million decrease in revenue recognized under the Betta Pharma collaboration, as a result higher program activity in the prior year.
CCCC 10-Kaccession 0001628280-26-012000
Sentence• a $11.2 million increase in revenue recognized from the Merck KGaA collaboration reflecting the prioritization of one KRAS project;
CCCC 10-Kaccession 0001628280-26-012000
Sentence• a $4.8 million increase in revenue related to the Roche collaboration as the two active programs in the collaboration have progressed to the lead series identification achievement phase in 2025, and a milestone was earned for each program;
CCCC 10-Kaccession 0001628280-26-012000
Linked news
Expected move
Inputsstraddle ±18.9%
spot 3.37exp Nov 20ATM strike 3ATM straddle 0.75IV 113%